Highlights

  • Dimerix shares climbed 19.39% to AUD 0.20 during the morning session on 16 June 2026.
  • The company signed an exclusive licensing agreement with Everest Medicines for DMX-200 across Greater China, South Korea and selected Southeast Asian markets.
  • Dimerix is eligible to receive a US$10 million (approximately AUD 14.1 million) upfront payment.
  • The agreement includes potential milestone payments of up to US$330 million (approximately AUD 467 million) plus tiered royalties on net sales.

Dimerix Limited (ASX:DXB) recorded a sharp share price gain during the morning session on 16 June 2026, with the stock rising 19.39% to AUD 0.20 after the biotechnology company announced a significant licensing agreement for its lead drug candidate, DMX-200.

The market responded positively to news that Dimerix had granted Everest Medicines exclusive rights to commercialise DMX-200 across Greater China, South Korea and several Southeast Asian countries. The agreement broadens the potential commercial reach of the company's Phase 3 kidney disease treatment while providing access to upfront payments, potential milestone revenue and future royalty streams.

Despite the day's rally, Dimerix shares remain down 61.37% over the past twelve months, highlighting the importance investors continue to place on clinical and commercial milestones associated with the company's lead development program.

About Dimerix

Dimerix is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory diseases, with a particular emphasis on kidney disorders.

The company's lead asset, DMX-200, is currently being developed for the treatment of Focal Segmental Glomerulosclerosis (FSGS), a rare and serious kidney disease that currently lacks approved therapies in many regions around the world.

DMX-200 was identified using Dimerix's proprietary Receptor-HIT technology platform, which is designed to improve understanding of receptor interactions and assist in identifying new therapeutic opportunities.

The company is currently progressing DMX-200 through the ACTION3 Phase 3 clinical study, which represents the most advanced stage of drug development before potential regulatory approval.

Major Licensing Agreement Opens Key Asian Markets

At the centre of the announcement is an exclusive licensing agreement that grants Everest Medicines commercialisation rights for DMX-200 across a broad group of Asian territories.

The licensed markets include mainland China, Hong Kong SAR, Macao SAR, Taiwan region, South Korea, Singapore, Malaysia, Thailand, Indonesia, Vietnam and the Philippines.

Under the arrangement, Everest Medicines will be responsible for commercialisation activities and regulatory submissions within these territories, while Dimerix will continue managing and funding the global Phase 3 clinical trial program.

Importantly, Dimerix retains rights to DMX-200 in all territories that have not already been licensed to regional partners.

The agreement represents the fifth licensing transaction completed for DMX-200, following previous regional partnerships announced since 2023.

Financial Terms Highlight Potential Value of the Deal

One of the key factors likely drawing investor attention was the scale of the financial package attached to the agreement.

Under the terms of the deal, Dimerix will receive an upfront payment of US$10 million, equivalent to approximately AUD 14.1 million, within 45 business days of execution.

Beyond the initial payment, the company may become eligible for development and regulatory milestone payments of up to US$30 million, or approximately AUD 42.4 million.

Commercial milestone payments could add a further US$300 million, equivalent to approximately AUD 424.4 million.

Collectively, the transaction carries potential value of up to approximately AUD 481 million in upfront and milestone payments, excluding any royalty revenue.

The agreement also includes tiered royalties ranging between 10% and 15% on net sales generated within the licensed territories.

While milestone payments remain dependent on future development, regulatory and commercial achievements, the deal materially expands the potential economic opportunity associated with DMX-200.

Fifth Regional Licensing Deal for DMX-200

The Everest Medicines transaction continues Dimerix's strategy of securing regional commercialisation partners for DMX-200.

Prior agreements have been signed with Advanz Pharma, Taiba Rare, Fuso Pharmaceutical Industries and Amicus Therapeutics, which has since become part of BioMarin.

According to the company, more than AUD 65 million had already been received under previous licensing arrangements before the Everest transaction was announced.

Following completion of all five agreements, Dimerix stated that it could potentially become eligible for approximately AUD 1.9 billion in aggregate upfront and milestone payments, in addition to future royalty streams from product sales.

The latest agreement therefore adds another major geographic region to the company's existing commercialisation network.

Large Untapped Patient Population in Licensed Territories

The new agreement targets regions where the burden of FSGS is significant and treatment options remain limited.

Dimerix cited estimates suggesting that between 500,000 and one million people may be living with FSGS across the licensed territories.

FSGS is a progressive kidney disorder characterised by scarring of the kidney's filtering units, resulting in proteinuria, declining kidney function and, in many cases, progression to end-stage kidney disease.

Current treatment approaches typically rely on non-specific therapies, and no approved treatments for FSGS currently exist across the regions covered by the licensing agreement.

The company believes the partnership with Everest Medicines could improve access to DMX-200 should the therapy ultimately obtain regulatory approvals.

Phase 3 Program Continues to Advance

Alongside the commercial update, investors are also closely monitoring progress of the ACTION3 Phase 3 clinical trial.

Dimerix confirmed that the adult cohort of the pivotal study is fully recruited, with 333 patients enrolled across 21 countries.

Importantly, patients from several of the newly licensed territories, including mainland China, Hong Kong SAR, Taiwan region, Thailand and Malaysia, are participating in the trial.

The study is evaluating DMX-200 as a treatment for FSGS and represents a critical step toward potential future regulatory submissions.

According to the company, interim data reported in early 2024 showed DMX-200 performing better than placebo in reducing proteinuria at that stage of the study.

Proteinuria, the presence of excess protein in urine, is a key indicator of kidney disease progression and is a major endpoint within the ACTION3 trial.

Recent Reviews Continue to Support Trial Progress

Dimerix also highlighted several developments related to the ongoing evaluation of ACTION3.

The company stated that no safety concerns have been identified to date following eight separate reviews conducted by the independent data monitoring committee, including the most recent review completed in June 2026.

In April 2026, the company also announced results from an external blinded statistical review of the trial.

According to Dimerix, the review confirmed that the study remains appropriately powered, with greater than 90% statistical power to detect a treatment effect for the primary endpoint of proteinuria if the anticipated reduction continues through trial completion.

Management indicated that these assessments support ongoing progression of the study as planned.

Everest Medicines Brings Regional Kidney Disease Expertise

Dimerix selected Everest Medicines as its commercialisation partner based on the company's existing capabilities in kidney disease and its presence across the licensed markets.

Everest has established operations focused on discovering, developing and commercialising therapies addressing unmet medical needs.

Its strategic focus includes cardiovascular, kidney and metabolic diseases, making the company a logical regional partner for DMX-200.

Under the agreement, Everest will handle regulatory submissions, commercial activities and market access initiatives within the licensed territories.

The companies will also establish a Joint Steering Committee to coordinate development and commercialisation activities related to FSGS within the covered regions.

Expanding Global Commercialisation Strategy

The Everest transaction forms part of Dimerix's broader strategy of building a global commercial framework around DMX-200 while maintaining control over development activities.

By partnering with regional pharmaceutical companies, Dimerix is seeking to leverage local expertise and infrastructure without bearing the full cost of commercial expansion across multiple international markets.

At the same time, the company continues to retain rights in territories that have not yet been licensed, preserving opportunities for future agreements.

The latest partnership significantly extends the potential commercial footprint of DMX-200 into some of the world's largest healthcare markets.

What This Means for Investors?

Dimerix's latest announcement represents a significant commercial milestone for DMX-200. The agreement with Everest Medicines provides access to Greater China, South Korea and several Southeast Asian markets through a licensing structure that includes a US$10 million upfront payment, potential milestone payments of up to US$330 million and future royalty opportunities.

The transaction also marks the fifth regional licensing agreement completed for DMX-200 and expands the drug candidate's potential reach into territories where between 500,000 and one million people are estimated to be living with FSGS. With the ACTION3 Phase 3 trial fully recruited and continuing to progress, investors are likely to remain focused on future clinical, regulatory and commercial developments associated with the program.